Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Boehringer Ingelheim
Fuji
Chinese Patent Office
UBS

Generated: August 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,518,446

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,518,446 protect, and when does it expire?

Patent 8,518,446 protects NERLYNX and is included in one NDA.

This patent has fourteen patent family members in nine countries.

Summary for Patent: 8,518,446
Title:Coated tablet formulations and uses thereof
Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.
Inventor(s): Ashraf; Muhammad (Elmwood, NJ), Mahmud; Mainuddin (Oak Ridge, NJ), Goolcharran; Chimanlall (East Lyme, CT), Ghosh; Krishnendu (Sparkill, NY), Nagi; Arwinder Singh (Moorpark, CA)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:12/940,808
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Dosage form;

Drugs Protected by US Patent 8,518,446

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,518,446

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 078952 ➤ Sign Up
Australia 2010316683 ➤ Sign Up
Canada 2780428 ➤ Sign Up
China 102724970 ➤ Sign Up
China 103893140 ➤ Sign Up
European Patent Office 2498756 ➤ Sign Up
Japan 2011098964 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Harvard Business School
Johnson and Johnson
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.